BR112021021826A2 - Combination therapies comprising apremilast and tyk2 inhibitors - Google Patents

Combination therapies comprising apremilast and tyk2 inhibitors

Info

Publication number
BR112021021826A2
BR112021021826A2 BR112021021826A BR112021021826A BR112021021826A2 BR 112021021826 A2 BR112021021826 A2 BR 112021021826A2 BR 112021021826 A BR112021021826 A BR 112021021826A BR 112021021826 A BR112021021826 A BR 112021021826A BR 112021021826 A2 BR112021021826 A2 BR 112021021826A2
Authority
BR
Brazil
Prior art keywords
apremilast
combination therapies
tyk2
tyk2 inhibitors
inhibitors
Prior art date
Application number
BR112021021826A
Other languages
Portuguese (pt)
Other versions
BR112021021826A8 (en
Inventor
Gilles Buchwalter
Lisa Beebe
Mary Adams
Henry Schafer Peter
Robert Plenge
Te-Chen Tzeng
Tiffany Carr
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of BR112021021826A2 publication Critical patent/BR112021021826A2/en
Publication of BR112021021826A8 publication Critical patent/BR112021021826A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

terapias combinadas compreendendo apremilaste e inibidores de tyk2. são fornecidos nesse documento métodos de tratamento de doenças e transtornos responsivos à inibição de pde4, compreendendo a administração de apremilaste e um inibidor de tyk2 a um indivíduo. também são fornecidas nesse documento composições farmacêuticas compreendendo apremilaste e um inibidor de tyk2.combination therapies comprising apremilast and tyk2 inhibitors. provided herein are methods of treating diseases and disorders responsive to pde4 inhibition, comprising administering apremilast and a tyk2 inhibitor to a subject. also provided herein are pharmaceutical compositions comprising apremilast and a tyk2 inhibitor.

BR112021021826A 2019-04-30 2020-04-30 Use of apremilast and a tyrosine kinase 2 inhibitor in the treatment of a disease or disorder responsive to phosphodiesterase type 4 inhibition BR112021021826A8 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2019/029772 WO2020222773A1 (en) 2019-04-30 2019-04-30 Combination therapies comprising apremilast and tyk2 inhibitors
PCT/US2020/030608 WO2020223431A1 (en) 2019-04-30 2020-04-30 Combination therapies comprising apremilast and tyk2 inhibitors

Publications (2)

Publication Number Publication Date
BR112021021826A2 true BR112021021826A2 (en) 2022-01-04
BR112021021826A8 BR112021021826A8 (en) 2022-06-21

Family

ID=66476870

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112021021809A BR112021021809A2 (en) 2019-04-30 2019-04-30 Combination therapies comprising apremilast and tyk2 inhibitors
BR112021021826A BR112021021826A8 (en) 2019-04-30 2020-04-30 Use of apremilast and a tyrosine kinase 2 inhibitor in the treatment of a disease or disorder responsive to phosphodiesterase type 4 inhibition

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112021021809A BR112021021809A2 (en) 2019-04-30 2019-04-30 Combination therapies comprising apremilast and tyk2 inhibitors

Country Status (14)

Country Link
EP (2) EP3962475A1 (en)
JP (2) JP2022537877A (en)
KR (2) KR20220002488A (en)
CN (2) CN114269336A (en)
AU (2) AU2019443366A1 (en)
BR (2) BR112021021809A2 (en)
CA (2) CA3138473A1 (en)
CL (1) CL2021002847A1 (en)
CO (2) CO2021015622A2 (en)
IL (2) IL287665A (en)
MA (1) MA55799A (en)
MX (2) MX2021013317A (en)
SG (2) SG11202112043PA (en)
WO (2) WO2020222773A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022537877A (en) 2019-04-30 2022-08-31 セルジーン コーポレイション Combination therapy including apremilast and a TYK2 inhibitor
WO2022175752A1 (en) 2021-02-19 2022-08-25 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
WO2023049241A1 (en) * 2021-09-23 2023-03-30 Bristol-Myers Squibb Company Methods of treating hair-loss disorders with tyk2 inhibitors
CA3236262A1 (en) 2021-10-25 2023-05-04 Isaac Marx Tyk2 degraders and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
US8367689B2 (en) * 2009-05-06 2013-02-05 Portola Pharmaceuticals, Inc. Inhibitors of JAK
AU2011328237A1 (en) 2010-11-09 2013-05-23 Cellzome Limited Pyridine compounds and aza analogues thereof as TYK2 inhibitors
ES2661583T3 (en) * 2011-04-28 2018-04-02 Celgene Corporation  Methods and compositions using PDE4 inhibitors for the treatment and management of autoimmune and inflammatory diseases
ES2799448T3 (en) 2011-12-27 2020-12-17 Amgen Europe Gmbh Formulations of (+) - 2- [1- (3-ethoxy-4-methoxy-phenyl) -2-methanesulfonyl-ethyl] -4-acetyl-aminoisoindoline-1,3-dione
EP2802567B1 (en) 2012-01-10 2017-03-01 F. Hoffmann-La Roche AG Pyridazine amide compounds and their use as syk inhibitors
EP2832734A4 (en) 2012-03-28 2015-08-26 Takeda Pharmaceutical Heterocyclic compound
WO2013174895A1 (en) 2012-05-24 2013-11-28 Cellzome Limited Heterocyclyl pyrimidine analogues as tyk2 inhibitors
CN104903301B (en) * 2012-11-08 2017-08-29 百时美施贵宝公司 Pyrimidine compound available for the alkylamide substitution of regulation IL 12, IL 23 and/or IFN α
EP2922846B1 (en) 2012-11-08 2018-10-03 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn-alpha
BR112015020584A2 (en) * 2013-03-14 2017-07-18 Celgene Corp Methods for treating psoriatic arthritis using apremilast
EP3029031A4 (en) 2013-07-30 2017-01-11 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2015032423A1 (en) 2013-09-03 2015-03-12 Sareum Limited Pharmaceutical compounds
TWI582077B (en) 2013-11-07 2017-05-11 必治妥美雅史谷比公司 Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnα responses
ES2702126T3 (en) 2013-12-10 2019-02-27 Bristol Myers Squibb Co Imidazopyridazine compounds useful as modulators of responses to IL-12, IL-23 and / or IFN alpha
WO2015091584A1 (en) 2013-12-18 2015-06-25 F. Hoffmann-La Roche Ag Thiazolopyridine compounds, compositions and their use as tyk2 kinase inhibitors
US9834548B2 (en) * 2014-02-14 2017-12-05 Portola Pharmaceuticals, Inc. Pyridazine compounds as JAK inhibitors
WO2015131080A1 (en) 2014-02-28 2015-09-03 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
MX2016014384A (en) 2014-06-23 2017-01-20 Celgene Corp Apremilast for the treatment of a liver disease or a liver function abnormality.
WO2016025686A1 (en) * 2014-08-15 2016-02-18 Celgene Corporation Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
NO2721710T3 (en) 2014-08-21 2018-03-31
WO2016047678A1 (en) 2014-09-25 2016-03-31 武田薬品工業株式会社 Heterocyclic compound
TWI788655B (en) 2015-02-27 2023-01-01 美商林伯士拉克許米公司 Tyk2 inhibitors and uses thereof
EP4327809A3 (en) 2015-09-02 2024-04-17 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
EP3419978B1 (en) 2016-02-24 2020-04-15 Pfizer Inc Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
US10836770B2 (en) 2016-10-07 2020-11-17 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or INF alpha responses
TWI763722B (en) 2016-10-14 2022-05-11 美商林伯士拉克許米公司 Tyk2 inhibitors and uses thereof
CN110300590A (en) 2016-10-21 2019-10-01 林伯士拉克许米公司 TYK2 inhibitor and application thereof
MA46620A (en) 2016-10-28 2021-05-26 Bristol Myers Squibb Co USEFUL HETEROBICYCLIC COMPOUNDS AS MODULATORS OF RESPONSES TO IL-12, IL-23 AND / OR IFN ALPHA
US11299494B2 (en) 2016-11-17 2022-04-12 Bristol-Myers Squibb Company Substituted imidazo[1,2-b]pyridazines as interleukin-23 and interferon-α modulators
GB2562702B (en) 2017-03-06 2022-05-18 Linear Shaped Ltd Frame and linear shaped charge
AR111233A1 (en) * 2017-03-08 2019-06-19 Nimbus Lakshmi Inc TYK2 INHIBITORS, USES AND METHODS FOR THE PRODUCTION OF THE SAME
JP2022537877A (en) 2019-04-30 2022-08-31 セルジーン コーポレイション Combination therapy including apremilast and a TYK2 inhibitor

Also Published As

Publication number Publication date
CN114269336A (en) 2022-04-01
AU2019443366A1 (en) 2021-12-02
EP3962476A1 (en) 2022-03-09
KR20220002488A (en) 2022-01-06
MX2021013317A (en) 2022-01-18
CA3138473A1 (en) 2020-11-05
JP2022537878A (en) 2022-08-31
WO2020223431A1 (en) 2020-11-05
CL2021002847A1 (en) 2022-07-22
WO2020222773A1 (en) 2020-11-05
CO2021015614A2 (en) 2021-12-10
CN114206333A (en) 2022-03-18
MA55799A (en) 2022-03-09
IL287670A (en) 2021-12-01
JP2022537877A (en) 2022-08-31
AU2020266143A1 (en) 2021-12-02
MX2021013318A (en) 2022-01-31
JP7453251B2 (en) 2024-03-19
SG11202112018YA (en) 2021-11-29
IL287665A (en) 2022-07-01
BR112021021809A2 (en) 2022-01-04
SG11202112043PA (en) 2021-11-29
CO2021015622A2 (en) 2022-02-28
BR112021021826A8 (en) 2022-06-21
KR20220002489A (en) 2022-01-06
CA3138686A1 (en) 2020-11-05
EP3962475A1 (en) 2022-03-09

Similar Documents

Publication Publication Date Title
BR112021021826A2 (en) Combination therapies comprising apremilast and tyk2 inhibitors
BR112023015527A2 (en) CDK INHIBITORS AND METHODS OF USE THEREOF
EA202190630A1 (en) COMBINED THERAPY METHODS
EA202092490A1 (en) METHYL-MODIFYING ENZYMES MODULATORS, COMPOSITIONS AND THEIR APPLICATION
BR112021022457A2 (en) fgfr inhibitors and methods of using them
BR112016020199A8 (en) human plasma kallikrein inhibitor compound, pharmaceutical composition comprising said compound, kit and its use
PH12020551425A1 (en) Rimegepant for cgrp related disorders
EA201892075A1 (en) COMBINATION OF LSD1 INHIBITORS FOR USE FOR THE TREATMENT OF SOLID TUMORS
MY195561A (en) Indole Carboxamide Compounds useful as Kinase Inhibitors
BR112018072545A2 (en) arginase inhibitors and their therapeutic applications
BR112022002905A2 (en) COMPOSITIONS AND METHODS TO MODULATE SPLICING AND PROTEIN EXPRESSION
BR112019025049A2 (en) RINGS 6- 5 CAST AS C5A INHIBITORS
BR112022000019A2 (en) Formula compound, pharmaceutical composition and cancer treatment method
EA201892219A1 (en) SUBSTITUTED INDIN DERIVATIVES AS AN INHIBITORS OF DENG VIRUS REPLICATION
BR112017009647A2 (en) 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors to treat alzheimer's disease
EA201892216A1 (en) SUBSTITUTED INDIN DERIVATIVES AS AN INHIBITORS OF DENG VIRUS REPLICATION
BR112019019193A2 (en) pyrimidinyl-pyridyloxy-naphthyl compounds and methods to treat ire-1 related diseases and disorders
BR112019025230A2 (en) RINGS 5-5 CAST AS C5A INHIBITORS
BR112021006319A2 (en) indolinone compounds for use as map4k1 inhibitors
BR112019004248A2 (en) dopamine b-hydroxylase inhibitors
EA202191955A1 (en) MODIFIED RELEASE TABLET FORMULATIONS CONTAINING PHOSPHODIESTERASE INHIBITORS
BR112022009710A2 (en) COMBINATION THERAPY COMPRISING AN ALK2 INHIBITOR AND A JAK2 INHIBITOR
MX2018008903A (en) COMPOSITIONS AND METHODS OF USE OF ß-HYDROXY-ß-METHYLBUTYRATE (HMB) FOR MODULATING AUTOPHAGY AND LIPOPHAGY.
BR112022000855A2 (en) nlrp3 modulators
BR112022008580A2 (en) METHODS TO TREAT DEPRESSIVE DISORDERS